FDA Approves Second Interchangeable Insulin Product, Rezvoglar (insulin glargine-aglr)

The US Food and Drug Administration (FDA) has recently granted approval for Rezvoglar, making it the second interchangeable insulin product available on the market. Rezvoglar, also known as insulin glargine-aglr, is a long-acting insulin that can now be substituted for other similar insulins without the need for additional safety or efficacy concerns. In this blog post, we will focus on the key points surrounding the FDA approval of Rezvoglar and the significance of having interchangeable insulin products.

1. Interchangeable Insulin Products

Interchangeable insulin products are a type of insulin that can be substituted for another without the need for additional oversight or concern regarding safety and efficacy. This means that patients can switch between interchangeable insulin products, including Rezvoglar, without needing prior approval from their healthcare provider. The availability of interchangeable insulins provides more options for patients living with diabetes and may contribute to improved access and affordability.

2. Rezvoglar: Insulin Glargine-aglr

Rezvoglar, developed by an undisclosed pharmaceutical company, is a biosimilar insulin glargine product. Insulin glargine is a long-acting insulin analog that helps regulate blood sugar levels in individuals with diabetes. It is typically used once daily and provides a steady release of insulin over an extended period. Rezvoglar has now been approved as an interchangeable option, indicating that it is deemed therapeutically equivalent to other available insulins of the same class.

3. FDA Approval Process for Interchangeable Insulins

To gain interchangeable status, insulin products must undergo rigorous evaluation and meet specific criteria established by the FDA. These criteria ensure that the interchangeable product is highly similar to the reference product in terms of safety, efficacy, and intended use. The FDA evaluates extensive data, including analytical, preclinical, and clinical studies, to assess whether the interchangeable product can produce the same clinical result as the reference product.

4. Increased Access and Affordability

The approval of Rezvoglar as an interchangeable insulin product has the potential to improve access and affordability for patients with diabetes. Interchangeable products provide alternatives to brand-name insulins, potentially offering cost savings and reducing barriers to treatment. It also grants healthcare providers more flexibility in prescribing the most suitable insulin for their patients, taking into account individual needs and financial considerations.

5. Addressing the Rising Costs of Insulin

Insulin affordability has been a significant concern in recent years, with the rising prices putting a financial strain on individuals with diabetes. The availability of interchangeable insulin products like Rezvoglar may help address this issue by increasing competition in the insulin market and potentially lowering prices. This step towards increased affordability is crucial in ensuring that all individuals with diabetes can access and afford the life-saving medications they need.

6. Ensuring Patient Safety and Education

Interchangeable insulin products like Rezvoglar offer benefits in terms of access and affordability. However, it is essential for patients and healthcare providers to remain vigilant and informed about the proper use and potential differences between interchangeable and reference insulins. Education about the availability, correct administration, and proper storage of interchangeable insulins is crucial to ensure patient safety and optimize treatment outcomes.


The FDA’s approval of Rezvoglar as the second interchangeable insulin product is a significant development in the field of diabetes treatment. This designation enables patients to switch between interchangeable insulins without additional safety or efficacy concerns. The availability of interchangeable insulin products like Rezvoglar is an important step towards improving access and affordability for individuals with diabetes. While these advancements offer promising solutions to rising insulin costs, it remains essential for patients and healthcare providers to stay informed and educated about the proper use of interchangeable insulins to ensure optimal patient outcomes and safety.